FMP
Comparative Analysis of Biotech Companies' Capital Efficiency
Jun 6, 2025 8:00 PM - Gordon Thompson(Last modified: Jun 9, 2025 1:19 PM)
Image credit: insspirito
- AnaptysBio, Inc. (NASDAQ:ANAB) is struggling with a ROIC of -26.40% against a WACC of 12.23%, indicating poor capital utilization.
- Similar challenges are observed in Deciphera Pharmaceuticals, Inc. (DCPH), Crinetics Pharmaceuticals, Inc. (CRNX), Rhythm Pharmaceuticals, Inc. (RYTM), and Kura Oncology, Inc. (KURA) with negative ROIC to WACC ratios, highlighting inefficiencies in capital utilization.
- CytomX Therapeutics, Inc. (CTMX) showcases effective capital utilization with a ROIC of 66.72% and a WACC of 13.54%, indicating strong growth potential.
AnaptysBio, Inc. (NASDAQ:ANAB) is a biotechnology company focused on developing antibody therapeutics for inflammation and immuno-oncology. The company is currently facing challenges in generating returns on its invested capital. AnaptysBio's ROIC is -26.40%, which is significantly lower than its WACC of 12.23%. This indicates that the company is not effectively using its capital to generate returns.
In comparison, Deciphera Pharmaceuticals, Inc. (DCPH) also shows a negative ROIC of -29.48% against a WACC of 5.15%. This results in a ROIC to WACC ratio of -5.72, suggesting that Deciphera is facing similar challenges in capital efficiency. Crinetics Pharmaceuticals, Inc. (CRNX) follows closely with a ROIC of -28.74% and a WACC of 5.29%, leading to a ROIC to WACC ratio of -5.44.
Rhythm Pharmaceuticals, Inc. (RYTM) presents a more concerning picture with a ROIC of -62.80% and a WACC of 15.33%. This results in a ROIC to WACC ratio of -4.10, indicating significant inefficiencies in capital utilization. Kura Oncology, Inc. (KURA) also struggles with a ROIC of -31.40% and a WACC of 5.98%, resulting in a ROIC to WACC ratio of -5.26.
CytomX Therapeutics, Inc. (CTMX) stands out positively with a ROIC of 66.72% and a WACC of 13.54%. This results in a ROIC to WACC ratio of 4.93, highlighting its effective capital utilization. CytomX's ability to generate returns that exceed its cost of capital sets it apart from its peers, showcasing its strong growth potential.
Other Blogs
Nov 22, 2024 5:08 AM - Parth Sanghvi
Fundamental Analysis: Principles, Types, and How to Use It
Fundamental analysis is one of the most essential tools for investors and analysts alike, helping them assess the intrinsic value of a stock, company, or even an entire market. It focuses on the financial health and economic position of a company, often using key data such as earnings, expenses, ass...
Dec 17, 2024 8:58 AM - Sanzhi Kobzhan
Examining Tesla’s Financial Health Using FinancialModelingPrep’s Ratios API
Tesla, one of the world’s most talked-about electric vehicle manufacturers, attracts a lot of attention from investors and market watchers. By examining a snapshot of Tesla’s financial ratios—such as those provided by FinancialModelingPrep’s Ratios API—we can get a clearer picture of the company’s f...
Dec 22, 2024 7:59 AM - Sanzhi Kobzhan
Two great Software Platform Stocks Similar to Palantir (PLTR)
When it comes to cutting-edge software and data analytics, Palantir Technologies (NYSE: PLTR) is often front and center. But for many investors, it’s important to consider alternative or complementary stocks in the same sector that may offer robust growth potential. As PLTR looks expensive (overvalu...
